These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27866832)

  • 21. Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
    Dickson PI
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of the treatment of lysosomal deposit diseases: Analysis of 22 patients.
    Canales-Siguero D; García-Muñoz C; Quijada Fraile P; Morales Conejo M; Ferrari-Piquero JM; Martín-Hernández E
    Med Clin (Barc); 2022 Oct; 159(8):380-384. PubMed ID: 35688745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Political Case of Penetrating Cranial Trauma: The Injury of James Scott Brady.
    Menger R; Kalakoti P; Hanif R; Ahmed O; Nanda A; Guthikonda B
    Neurosurgery; 2017 Sep; 81(3):545-551. PubMed ID: 28531301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orphan drug development.
    Pastores GM; Gupta P
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():64-7. PubMed ID: 24380124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pioneer in behavioral pharmacology: a tribute to Joseph V. Brady.
    Barrett JE
    J Exp Anal Behav; 2008 Nov; 90(3):405-15. PubMed ID: 19070344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
    Desnick RJ; Schuchman EH
    Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory watch: enhanced chance of success for protein replacement therapies.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jun; 12(6):414. PubMed ID: 23722335
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging drugs for lysosomal storage diseases.
    Beck M
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):495-507. PubMed ID: 20557271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joseph v. Brady: synthesis reunites what analysis has divided.
    Thompson T
    Behav Anal; 2012; 35(2):197-208. PubMed ID: 23450040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximizing the therapeutic potential of enzyme replacement therapy for lysosomal storage diseases.
    Gieselmann V
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):707-8. PubMed ID: 19954707
    [No Abstract]   [Full Text] [Related]  

  • 33. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From serendipity to therapy.
    Neufeld EF
    Annu Rev Biochem; 2011; 80():1-15. PubMed ID: 21675915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enzyme replacement therapy for Gaucher disease introduced in late adulthood].
    Juhász P; Tóth B; Maródi L; Erdos M
    Orv Hetil; 2012 Feb; 153(7):264-70. PubMed ID: 22318527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experiences of patients with lysosomal storage disorders receiving enzyme replacement therapy.
    Nurs Health Sci; 2022 Sep; 24(3):789-792. PubMed ID: 35789527
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.